IRIS
RIZZOLI, Vittorio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.613
AS - Asia 5.181
EU - Europa 3.997
SA - Sud America 722
AF - Africa 252
Continente sconosciuto - Info sul continente non disponibili 17
OC - Oceania 2
Totale 15.784
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.426
SG - Singapore 2.111
CN - Cina 1.857
IE - Irlanda 760
FI - Finlandia 741
SE - Svezia 738
BR - Brasile 572
UA - Ucraina 560
DE - Germania 537
HK - Hong Kong 384
VN - Vietnam 310
TR - Turchia 264
NL - Olanda 180
ZA - Sudafrica 166
CA - Canada 135
IT - Italia 120
GB - Regno Unito 107
IN - India 67
AR - Argentina 60
FR - Francia 50
RU - Federazione Russa 49
CI - Costa d'Avorio 42
BD - Bangladesh 34
EC - Ecuador 34
MX - Messico 34
BE - Belgio 31
IQ - Iraq 26
RO - Romania 25
JP - Giappone 23
IR - Iran 22
PL - Polonia 22
ID - Indonesia 17
CZ - Repubblica Ceca 15
EU - Europa 15
CO - Colombia 14
ES - Italia 12
MA - Marocco 12
LT - Lituania 11
UY - Uruguay 10
AT - Austria 9
PK - Pakistan 9
PE - Perù 8
PY - Paraguay 8
UZ - Uzbekistan 8
CL - Cile 7
AE - Emirati Arabi Uniti 6
EG - Egitto 6
KE - Kenya 6
LV - Lettonia 6
VE - Venezuela 6
AL - Albania 5
DO - Repubblica Dominicana 5
JO - Giordania 5
TN - Tunisia 5
AZ - Azerbaigian 4
IL - Israele 4
SK - Slovacchia (Repubblica Slovacca) 4
CR - Costa Rica 3
DZ - Algeria 3
ET - Etiopia 3
KZ - Kazakistan 3
LK - Sri Lanka 3
NG - Nigeria 3
NP - Nepal 3
BB - Barbados 2
BG - Bulgaria 2
BO - Bolivia 2
GE - Georgia 2
GR - Grecia 2
HN - Honduras 2
HU - Ungheria 2
JM - Giamaica 2
KR - Corea 2
LU - Lussemburgo 2
MY - Malesia 2
NI - Nicaragua 2
OM - Oman 2
RS - Serbia 2
SA - Arabia Saudita 2
SN - Senegal 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
AU - Australia 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CH - Svizzera 1
CM - Camerun 1
GA - Gabon 1
GY - Guiana 1
HR - Croazia 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
PA - Panama 1
Totale 15.779
Salva come PNG Salva come JPEG
Città #
Singapore 1.063
Dublin 759
Chandler 711
Jacksonville 654
Ashburn 593
Beijing 448
Hong Kong 381
Santa Clara 367
Dearborn 253
Nanjing 237
Izmir 227
Boardman 224
Dallas 208
San Mateo 186
Princeton 160
Johannesburg 158
Ann Arbor 141
Los Angeles 137
Ho Chi Minh City 121
Toronto 105
Shanghai 103
Wilmington 98
Shenyang 88
Nanchang 82
Helsinki 76
Kunming 74
Hefei 73
Munich 70
Hebei 65
New York 65
Düsseldorf 63
Jinan 63
Hanoi 57
São Paulo 55
Parma 50
Des Moines 49
Buffalo 44
Abidjan 42
Woodbridge 40
Changsha 39
Marseille 37
Tianjin 37
Guangzhou 35
Jiaxing 35
Bremen 33
Moscow 33
Brussels 31
Columbus 31
Pune 29
Seattle 28
Kocaeli 26
Leawood 25
Turku 24
Zhengzhou 24
Stockholm 23
Grafing 22
Warsaw 21
Hangzhou 20
Tokyo 20
Augusta 19
Norwalk 19
Brooklyn 18
Houston 18
Da Nang 17
Atlanta 16
Haiphong 16
Ningbo 16
Focsani 15
London 15
Montreal 15
Rio de Janeiro 15
Mestre 14
San Francisco 14
Amsterdam 13
Lanzhou 13
Monmouth Junction 13
Phoenix 13
Ardabil 12
Boston 12
Denver 12
Fremont 12
Haikou 12
Nuremberg 12
Chicago 11
Chongqing 11
Orem 11
Taizhou 11
The Dalles 11
Brasília 10
Frankfurt am Main 10
Fuzhou 10
Quito 10
Timisoara 10
Guarulhos 9
Guayaquil 9
Porto Alegre 9
Redondo Beach 9
Thái Nguyên 9
Auburn Hills 8
Borås 8
Totale 9.480
Salva come PNG Salva come JPEG
Nome #
Are the Myeloma bone microevironment cells tumoral or not? 194
Diabetes impairs hematopoietic stem cell mobilization by altering niche function 187
Angiopoietin-1 and Osteopontin Expression by CD138+ Myeloma Cells Rather Than VEGF and CD45 Correlates with Bone Marrow Angiogenesis in Multiple Myeloma Patients at the Diagnosis 179
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 165
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 161
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 158
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 156
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia 156
The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment 154
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 152
Chemokine receptors CXCR3 and CXCR4 expression in B cell and plasma cell malignancy 150
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 148
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 145
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 142
Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. 141
Amifostine (WR-2721) selective protection against melphalan genotoxicity 138
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 138
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 137
Angiopoietins expression by human myeloma cells 136
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 136
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 136
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 134
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 134
A translocation t(4;13)(q21;q14) as single clonal chromosomal abnormality in a parathyroid adenoma 133
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 131
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. 129
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 129
Autologous bone marrow transplantation in acute myeloid leukemia: a single center experience 129
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 128
Angiopoietin-1 and osteopontin expression by CD138+myeloma cells rather than VEGF and CD45 correlates with bone marrow angiogenesis in Multiple Myeloma patients at the diagnosis. 128
Bleomycin Genotoxicity and Amifostine (WR-2721) Cell Protection in Normal Leukocytes versus K562 Tumoral Cells 128
Angiopoietin-1 and myeloma-induced angiogenesis 126
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 126
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: potential relationship with myeloma-induced angiogenesis 125
Angiogenic switch in multiple myeloma patients 124
Angiogenic properties of human myeloma cells: role of angiopoietin system 123
Analysis of lineage involvment in Philadelphia chromosome positive acute lymphoblastic leukaemia 123
Ectopic production of osteopontin by human myeloma cells and its involvement in myeloma induced angiogenesis 122
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 121
The new tumor suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro-angiogenic molecules by myeloma cells and suppresses hypoxia inducible factor (HIF)-1{alpha} activity being involved in myeloma-induced angiogenesis. 120
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 119
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis 118
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 117
Expression and role of chemokine receptor CXCR3 in multiple myeloma 117
Alterations of microenvironment in multiple myeloma patients: Interactions between myeloma cells and osteoprogenitor cells 117
Autotransplantation in acute leukemia. 115
Do human myeloma cells directly produce basic FGF? 115
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation 114
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients 114
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent anti-tumor activity in vivo against human multiple myeloma xenograft model. 114
Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets 113
Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation. 112
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment 111
Macrophage inflammatory protein (MIP)-3 alpha/CCL20 and its receptor CCR6 are overexpressed in the bone microenvironment and involved in osteoclast formation in multiple myeloma patients. 110
Angiogenic switch in multiple myeloma 109
EPIRUBICIN PLUS G-CSF ELICITED PERIPHERAL BLOOD PROGENITOR CELL MOBILIZATION IS SIGNIFICANTLY ENHANCED BY AMIFOSTINE 108
A distintive nuclear morfology in three cases of acute myeloid leukaemia associated with loss HLA-DR expression and FTL3 internal tandem duplication 108
Assessment of the efficacy of a last-generation polyvalent immunoglobulin in the treatment of idiopathic thrombocytopenic purpura. 108
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 107
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 106
Osteopontin is produced by human multiple myeloma cells 105
Pan-aurora kinase inhibitor MK-0457 synergistically potentiates Apo2l/TRAIL cytotoxicity in Multiple Mieloma cells sensitive and resistant to bortezomib 105
BCL2 oncogene protein expression in human hematopoietic precursors during fetal life. 104
Gamma-rays from Mössbauer sources: a low-dose approach to cancer therapy 104
Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation. 104
Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated marrow. 102
p29ING4 regulates the production of pro-angiogenic molecules by human myeloma cells in normoxic and hypoxic conditions being involved in myeloma-induced angiogenesis. 102
Beta-catenin depended and independent effects induced by myeloma cells in human and murine osteoblasts and osteoblast progenitors. 101
Arsenic trioxide in hematological malignancies: The new discovery of an ancient drug 101
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease 101
DNA damage by tobacco smoke and some antiblastic drugs evaluated using the Comet assay 99
Down-modulation of ERK protein kinase activity suppresses human myeloma cell proliferation and myeloma-induced angiogenesis by VEGF inhibition 98
Effects of Mössbauer radiation on bone marrow cultures 98
DKK-1 and sFRP-3 expression by myeloma cell and bone marrow plasma levels in multiple myeloma and MGUS patients: Potential relationship with bone status. 98
RANKL is critically involved in the physiopathology of multiple myeloma 96
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 95
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple Myeloma bone disease 95
VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group 94
Impact of XIAP protein levels on the survival of myeloma cells 94
Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens 94
HUMAN MYELOMA CELLS EXPRESS THE BONE REGULATING GENE RUNX2/CBFA1 AND PRODUCE OSTEOPONTIN THAT IT IS INVOLVED IN MYELOMA INDUCED ANGIOGENESIS 93
Mossbauer analysis of bone marrow before and after purging with Asta-z 7557 93
Multiple myeloma patient with unusual extramedullary involvement 93
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 92
The proteasome inhibitor bortezomib affects osteoblastogenesis and bone formation in vitro and in vivo in multiple myeloma patients. 92
Expression of pro-angiogenetic factors by myeloma cells: role of the angiopoietin system 91
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting 91
Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment? 90
Human myeloma cells produce angiopoietin-1: potential relationship with myeloma-induced angiogenesis 90
Human myeloma cells express IL-7 mRNA and secrete IL-7 in presence of IL-6 90
Purging the bone marrow in non-Hodgkin's lymphomas. Is there any evidence of its value? 90
MYELOMA CELLS BLOCK RUNX2/CBFA1 ACTIVITY IN HUMAN BONE MARROW OSTEOBLAST PROGENITORS AND INHIBIT OSTEOBLAST FORMATION AND DIFFERENTIATION 89
Role of tumor necrosis factor-related activation-induced cytokine (TRANCE) in multiple myeloma 88
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 88
Evaluation of amifostine (WR-271) cytoprotection against in vitro bleomycin-induced clastogenicity in human leukocytes by SCGE assay 87
Non-infusional vs intravenous consolidation chemotherapy in elderly patients withacute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase 86
IL-7 is produced by myeloma cells in presence of IL-6 86
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients 85
Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients 84
The proteasome inhibitor bortezomib stimulates the osteogenic differentiation of mesenchymal cells in vitro and may increase osteoblast formation in vivo in multiple myeloma patients. 83
Totale 11.645
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.640
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.640
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021729 0 0 0 0 0 6 120 9 274 37 254 29
2021/2022784 11 2 5 56 16 31 94 137 35 85 80 232
2022/20232.743 357 295 171 193 250 284 53 151 891 11 74 13
2023/2024866 40 105 21 16 75 196 82 89 22 41 69 110
2024/20252.899 52 178 198 202 313 284 47 93 419 283 242 588
2025/20263.828 576 589 763 665 1.006 229 0 0 0 0 0 0
Totale 15.877